EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia

Stella Settumba iD, Jeyran Shahbazi, Marianne Byrne, Louisa Degenhardt iD, Jason Grebely, Briony Larance iD, Suzanne Nielsen iD, Nicholas Lintzeris iD, Robert Ali iD, Craig Rodgers, Alison Blazey, Robert Weiss und 4 weitere

Drug and Alcohol Review · 2025

DOI: 10.1111/dar.13956 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Drug and Alcohol Review, 2025. Verfasst von Stella Settumba und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Buprenorphine, Health Care Costs, Narcotic Antagonists, Opiate Substitution Treatment. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, Indivior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The costs of providing medication‐assisted treatment for opioid dependence can determine its scale of provision. To provide estimates of the costs of extended‐release buprenorphine (BUP‐XR), we performed a bottom‐up costing analysis of provider operational treatment costs.

Methods

Data were collected in a single‐arm open label trial of BUP‐XR injections conducted in specialist public drug treatment services and primary care private practices in three Australian states (the CoLAB study). The unit costs of resources used for each activity were combined with quantities used at each participating facility to arrive at the average annual cost per client.

Results

One hundred participants across the six health facility sites received monthly subcutaneous BUP‐XR injections administered by a health‐care practitioner. The average cost of providing 1 year of treatment per participant was $6656 ($6026–$8326). Screening cost (initial assessment and medical history) was $282 while monthly follow‐up appointments cost $531 per client. The main cost driver was the monthly treatment costs accounting for 79% of the average annual client cost, with medication costs comprising 95% of this cost. Discussion and Conclusion With medication costs making up the largest proportion of treatment costs, treatment using BUP‐XR has the potential to free up other health system resources, for example, staff time. The costs reported in this study can be used in an economic evaluation to estimate the net benefit or cost‐effectiveness of BUP‐XR especially when compared to other opioid agonist treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineHealth Care CostsNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersAdultFemaleHumansMaleMiddle AgedAustraliaDelayed-Action Preparations

Stichwörter der Autor:innen

costs and cost analysisextended‐release buprenorphineopioid dependenceprovider perspective

Substanzen

BuprenorphineDelayed-Action PreparationsNarcotic Antagonists

Autor:innen und Institutionen

  • National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
  • The Kirby Institute, UNSW Sydney, Sydney, Australia.
  • School of Psychology, University of Wollongong, Wollongong, Australia.
  • Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia.
  • Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
  • Monash Addiction Research Centre and Eastern Health Clinical School, Monash University Peninsula Campus, Melbourne, Australia.

ORCID-Profile: Stella Settumba, Louisa Degenhardt, Briony Larance, Suzanne Nielsen, Nicholas Lintzeris, Robert Ali, Adrian Dunlop

Förderung

  • NIDA NIH HHS
  • Indivior

Zitieren

APA

Settumba, S., Shahbazi, J., Byrne, M., Degenhardt, L., Grebely, J., Larance, B., Nielsen, S., Lintzeris, N., Ali, R., Rodgers, C., Blazey, A., Weiss, R., Dunlop, A., McDonough, M., Cook, J., & Farrell, M. (2025). Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia. Drug and Alcohol Review. https://doi.org/10.1111/dar.13956

Vancouver

Settumba S, Shahbazi J, Byrne M, Degenhardt L, Grebely J, Larance B, et al. Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia. Drug and Alcohol Review. 2025. doi:10.1111/dar.13956

BibTeX
@article{Settumba2025,
  author = {Settumba, Stella and Shahbazi, Jeyran and Byrne, Marianne and Degenhardt, Louisa and Grebely, Jason and Larance, Briony and Nielsen, Suzanne and Lintzeris, Nicholas and Ali, Robert and Rodgers, Craig and Blazey, Alison and Weiss, Robert and Dunlop, Adrian and McDonough, Michael and Cook, Jon and Farrell, Michael},
  title = {Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia},
  journal = {Drug and Alcohol Review},
  year = {2025},
  doi = {10.1111/dar.13956}
}
Kostenlos starten →